Is there a Bearish outlook for Allergy Therapeutics plc (LON:AGY) this week?

June 16, 2018 - By Peter Erickson

Allergy Therapeutics plc (LON:AGY) Logo

Allergy Therapeutics plc (LON:AGY) Ratings Coverage

Among 2 analysts covering Allergy Therapeutics PLC (LON:AGY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Allergy Therapeutics PLC had 8 analyst reports since January 31, 2018 according to SRatingsIntel. FinnCap maintained the stock with “Corporate” rating in Thursday, February 1 report. Numis Securities maintained it with “Buy” rating and GBX 45 target in Wednesday, January 31 report. The company was maintained on Wednesday, March 7 by Numis Securities. Numis Securities maintained the stock with “Buy” rating in Monday, May 21 report. The firm has “Corporate” rating given on Monday, February 12 by FinnCap. The rating was maintained by FinnCap on Monday, May 21 with “Corporate”. On Wednesday, March 7 the stock rating was maintained by FinnCap with “Corporate”. The firm has “Corporate” rating given on Wednesday, February 28 by FinnCap. Below is a list of Allergy Therapeutics plc (LON:AGY) latest ratings and price target changes.

21/05/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 Maintain
21/05/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 Maintain
07/03/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 New Target: GBX 45.00 Maintain
07/03/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
28/02/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
12/02/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
01/02/2018 Broker: FinnCap Rating: Corporate Old Target: GBX 47.00 New Target: GBX 47.00 Maintain
31/01/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 45.00 New Target: GBX 45.00 Maintain

The stock decreased 1.85% or GBX 0.5 during the last trading session, reaching GBX 26.5. About 12,544 shares traded. Allergy Therapeutics plc (LON:AGY) has 0.00% since June 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Allergy Therapeutics plc, a specialty pharmaceutical company, focusing on allergy vaccination primarily in Europe. The company has market cap of 157.44 million GBP. The companyÂ’s primary flagship products consist of the Pollinex Quattro for the treatment of allergic conditions; and monophosphoryl-lipid A, a substance that enhances the immune response to an antigen or allergen. It currently has negative earnings. It offers sublingual product, including Oralvac Compact; Venomil product, which is used for the wasp and bee treatment; probiotic products, such as Kallergen-Th, ATI Prob, and Pollagen; Acarovac Plus, a novel tyrosine-adsorbed, modified-allergen product developed for treatment of perennial mite allergy; and DAP, a product for use in the diagnosis of type I or immediate hypersensitivity to benzyl penicillin and related antibiotics by means of cutaneous tests (prick and intradermal).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: